534 related articles for article (PubMed ID: 26160839)
1. Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism.
Chen GQ; Tang CF; Shi XK; Lin CY; Fatima S; Pan XH; Yang DJ; Zhang G; Lu AP; Lin SH; Bian ZX
Oncotarget; 2015 Sep; 6(27):24148-62. PubMed ID: 26160839
[TBL] [Abstract][Full Text] [Related]
2. Atractylenolide I inhibits colorectal cancer cell proliferation by affecting metabolism and stemness via AKT/mTOR signaling.
Wang K; Huang W; Sang X; Wu X; Shan Q; Tang D; Xu X; Cao G
Phytomedicine; 2020 Mar; 68():153191. PubMed ID: 32135457
[TBL] [Abstract][Full Text] [Related]
3. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells.
Sun Y; Gu X; Zhang E; Park MA; Pereira AM; Wang S; Morrison T; Li C; Blenis J; Gerbaudo VH; Henske EP; Yu JJ
Cell Death Dis; 2014 May; 5(5):e1231. PubMed ID: 24832603
[TBL] [Abstract][Full Text] [Related]
4. Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia.
Siska PJ; van der Windt GJ; Kishton RJ; Cohen S; Eisner W; MacIver NJ; Kater AP; Weinberg JB; Rathmell JC
J Immunol; 2016 Sep; 197(6):2532-40. PubMed ID: 27511728
[TBL] [Abstract][Full Text] [Related]
5. Halofuginone dually regulates autophagic flux through nutrient-sensing pathways in colorectal cancer.
Chen GQ; Gong RH; Yang DJ; Zhang G; Lu AP; Yan SC; Lin SH; Bian ZX
Cell Death Dis; 2017 May; 8(5):e2789. PubMed ID: 28492544
[TBL] [Abstract][Full Text] [Related]
6. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
[TBL] [Abstract][Full Text] [Related]
7. Foxp3 and Toll-like receptor signaling balance T
Gerriets VA; Kishton RJ; Johnson MO; Cohen S; Siska PJ; Nichols AG; Warmoes MO; de Cubas AA; MacIver NJ; Locasale JW; Turka LA; Wells AD; Rathmell JC
Nat Immunol; 2016 Dec; 17(12):1459-1466. PubMed ID: 27695003
[TBL] [Abstract][Full Text] [Related]
8. NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth.
Zha X; Hu Z; Ji S; Jin F; Jiang K; Li C; Zhao P; Tu Z; Chen X; Di L; Zhou H; Zhang H
Cancer Lett; 2015 Apr; 359(1):97-106. PubMed ID: 25578782
[TBL] [Abstract][Full Text] [Related]
9. DT-13 inhibited the proliferation of colorectal cancer via glycolytic metabolism and AMPK/mTOR signaling pathway.
Wei X; Mao T; Li S; He J; Hou X; Li H; Zhan M; Yang X; Li R; Xiao J; Yuan S; Sun L
Phytomedicine; 2019 Feb; 54():120-131. PubMed ID: 30668361
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
[TBL] [Abstract][Full Text] [Related]
11. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
[TBL] [Abstract][Full Text] [Related]
12. Metabolic phenotype of bladder cancer.
Massari F; Ciccarese C; Santoni M; Iacovelli R; Mazzucchelli R; Piva F; Scarpelli M; Berardi R; Tortora G; Lopez-Beltran A; Cheng L; Montironi R
Cancer Treat Rev; 2016 Apr; 45():46-57. PubMed ID: 26975021
[TBL] [Abstract][Full Text] [Related]
13. Delicaflavone induces ROS-mediated apoptosis and inhibits PI3K/AKT/mTOR and Ras/MEK/Erk signaling pathways in colorectal cancer cells.
Yao W; Lin Z; Shi P; Chen B; Wang G; Huang J; Sui Y; Liu Q; Li S; Lin X; Liu Q; Yao H
Biochem Pharmacol; 2020 Jan; 171():113680. PubMed ID: 31669234
[TBL] [Abstract][Full Text] [Related]
14. The tumor-suppressor gene LZTS1 suppresses colorectal cancer proliferation through inhibition of the AKT-mTOR signaling pathway.
Zhou W; He MR; Jiao HL; He LQ; Deng DL; Cai JJ; Xiao ZY; Ye YP; Ding YQ; Liao WT; Liu SD
Cancer Lett; 2015 Apr; 360(1):68-75. PubMed ID: 25667121
[TBL] [Abstract][Full Text] [Related]
15. Metabolic reprogramming and AMPKα1 pathway activation by caulerpin in colorectal cancer cells.
Yu H; Zhang H; Dong M; Wu Z; Shen Z; Xie Y; Kong Z; Dai X; Xu B
Int J Oncol; 2017 Jan; 50(1):161-172. PubMed ID: 27922662
[TBL] [Abstract][Full Text] [Related]
16. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
17. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
18. Effects of orexin A on glucose metabolism in human hepatocellular carcinoma in vitro via PI3K/Akt/mTOR-dependent and -independent mechanism.
Liu Y; Zhao Y; Guo L
Mol Cell Endocrinol; 2016 Jan; 420():208-16. PubMed ID: 26549689
[TBL] [Abstract][Full Text] [Related]
19. 15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity.
Shin SW; Seo CY; Han H; Han JY; Jeong JS; Kwak JY; Park JI
Clin Cancer Res; 2009 Sep; 15(17):5414-25. PubMed ID: 19690198
[TBL] [Abstract][Full Text] [Related]
20. miRNA-451 inhibits glioma cell proliferation and invasion by downregulating glucose transporter 1.
Guo H; Nan Y; Zhen Y; Zhang Y; Guo L; Yu K; Huang Q; Zhong Y
Tumour Biol; 2016 Oct; 37(10):13751-13761. PubMed ID: 27476171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
